Targeting gastrointestinal stromal tumors: The role of regorafenib

Brett Schroeder, Zula Li, Lee D Cranmer, Robin L. Jones, Seth M. Pollack

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Gastrointestinal stromal tumor (GIST) is a devastating disease in the metastatic setting, but its natural history has been dramatically altered by the development of small molecule tyrosine kinase inhibitors, most notably imatinib. Although patients with advanced GIST live much longer today than they did in the past, imatinib-refractory disease remains a tremendous problem. For disease that is refractory to imatinib and sunitinib, regorafenib is an excellent option. In this review, we discuss the biology and clinical work establishing regorafenib as the standard of care for advanced GIST refractory to both imatinib and sunitinib.

Original languageEnglish (US)
Pages (from-to)3009-3016
Number of pages8
JournalOncoTargets and Therapy
Volume9
DOIs
StatePublished - May 20 2016
Externally publishedYes

Fingerprint

Gastrointestinal Stromal Tumors
Standard of Care
Natural History
Protein-Tyrosine Kinases
regorafenib
Imatinib Mesylate
sunitinib

Keywords

  • GIST
  • Imatinib
  • Refractory
  • Regorafenib

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

Targeting gastrointestinal stromal tumors : The role of regorafenib. / Schroeder, Brett; Li, Zula; Cranmer, Lee D; Jones, Robin L.; Pollack, Seth M.

In: OncoTargets and Therapy, Vol. 9, 20.05.2016, p. 3009-3016.

Research output: Contribution to journalArticle

Schroeder, Brett ; Li, Zula ; Cranmer, Lee D ; Jones, Robin L. ; Pollack, Seth M. / Targeting gastrointestinal stromal tumors : The role of regorafenib. In: OncoTargets and Therapy. 2016 ; Vol. 9. pp. 3009-3016.
@article{93e543dfb2f44719a8c5111cfcf35d4f,
title = "Targeting gastrointestinal stromal tumors: The role of regorafenib",
abstract = "Gastrointestinal stromal tumor (GIST) is a devastating disease in the metastatic setting, but its natural history has been dramatically altered by the development of small molecule tyrosine kinase inhibitors, most notably imatinib. Although patients with advanced GIST live much longer today than they did in the past, imatinib-refractory disease remains a tremendous problem. For disease that is refractory to imatinib and sunitinib, regorafenib is an excellent option. In this review, we discuss the biology and clinical work establishing regorafenib as the standard of care for advanced GIST refractory to both imatinib and sunitinib.",
keywords = "GIST, Imatinib, Refractory, Regorafenib",
author = "Brett Schroeder and Zula Li and Cranmer, {Lee D} and Jones, {Robin L.} and Pollack, {Seth M.}",
year = "2016",
month = "5",
day = "20",
doi = "10.2147/OTT.S104081",
language = "English (US)",
volume = "9",
pages = "3009--3016",
journal = "OncoTargets and Therapy",
issn = "1178-6930",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Targeting gastrointestinal stromal tumors

T2 - The role of regorafenib

AU - Schroeder, Brett

AU - Li, Zula

AU - Cranmer, Lee D

AU - Jones, Robin L.

AU - Pollack, Seth M.

PY - 2016/5/20

Y1 - 2016/5/20

N2 - Gastrointestinal stromal tumor (GIST) is a devastating disease in the metastatic setting, but its natural history has been dramatically altered by the development of small molecule tyrosine kinase inhibitors, most notably imatinib. Although patients with advanced GIST live much longer today than they did in the past, imatinib-refractory disease remains a tremendous problem. For disease that is refractory to imatinib and sunitinib, regorafenib is an excellent option. In this review, we discuss the biology and clinical work establishing regorafenib as the standard of care for advanced GIST refractory to both imatinib and sunitinib.

AB - Gastrointestinal stromal tumor (GIST) is a devastating disease in the metastatic setting, but its natural history has been dramatically altered by the development of small molecule tyrosine kinase inhibitors, most notably imatinib. Although patients with advanced GIST live much longer today than they did in the past, imatinib-refractory disease remains a tremendous problem. For disease that is refractory to imatinib and sunitinib, regorafenib is an excellent option. In this review, we discuss the biology and clinical work establishing regorafenib as the standard of care for advanced GIST refractory to both imatinib and sunitinib.

KW - GIST

KW - Imatinib

KW - Refractory

KW - Regorafenib

UR - http://www.scopus.com/inward/record.url?scp=84969504794&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84969504794&partnerID=8YFLogxK

U2 - 10.2147/OTT.S104081

DO - 10.2147/OTT.S104081

M3 - Article

AN - SCOPUS:84969504794

VL - 9

SP - 3009

EP - 3016

JO - OncoTargets and Therapy

JF - OncoTargets and Therapy

SN - 1178-6930

ER -